KEFPEP® preserves both bioactive peptides and probiotic metabolites, thanks to our unique core production techniques. The peptides have been shown to regulate blood pressure, increase Bone Mineral Density (BMD), and protect the liver against fat accumulation. More importantly, the production of our key ingredients is in compliance with international safety and efficacy guidelines. Thus, the materials developed by Phermpep are highly competitive and have great potential in markets with specific health claim regulations.
Peptide profiles produced using Phermpep's core techniques have been and continue to be patented in Taiwan, the US, Mainland China, and the EU. Currently, the application of KEFPEP® for increasing Bone Mineral Density (BMD) has been patented in the US. In Taiwan and Mainland China, relevant patents are in progress. Moreover, we have obtained other patents in metabolic syndrome prevention and vascular protection applications in Taiwan.
KEFPEP® has revealed antihypertensive activities on in vivo assays using Spontaneously Hypertensive Rats (SHR) and Spontaneously Hypertensive Stroke-Prone Rats (SHRSP). Clinical trials have also demonstrated that KEFPEP® lowers Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) in patients with prehypertension.
In addition, Administration of KEFPEP® protects the cardiovascular system against hypertension or high-salt diet-induced stresses. Following ingestion of high salt concentration, KEFPEP® has been found to protect the cardiovascular system, including aortic arch, renal artery, and cerebral artery, as well as ameliorate inflammation, thickening, and arteriosclerosis. Experimental results and clinical outcomes consistently suggest that KEFPEP® is an efficient peptide-based ingredient for blood pressure regulation and cardiovascular protection.
Ovariectomized rats are the commonly used animal model for mimicking osteoporosis in menopausal women. In ovariectomized rats, administration of KEFPEP® efficiently prevents the degeneration of trabecular bone and attenuates the decrease in bone mineral density (BMD). Therefore, treatment with KEFPEP® provides obvious benefits in maintaining structure and function of bone. The results of our clinical trial indicate that administration of KEFPEP® elevates serum Parathyroid Hormone (PTH) and suppresses osteoclast activity. Elevated PTH level then leads to bone formation activation. Therefore, treatment with KEFPEP® helps maintain and even increase BMD in patients with osteopenia and mild osteoporosis.
KEFPEP® has been shown to prevent fat accumulation in hepatocytes of leptin-deficient obese mice by suppressing the lipogenesis pathway. In addition, treatment with KEFPEP® significantly prevents the occurrence of fatty liver, even when the mice constantly drink water containing 30% fructose. Collectively, KEFPEP® is an efficient dietary supplement for preventing fatty liver.